GlassScriptPhysician profile
Andrew S Pettit
NPI 1487200853
$2,975.66
in general payments reported to CMS, 2019-2025
34 companies · $880 in 2025
The $880 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $253 · 2022: $146 · 2023: $886 · 2024: $811 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,576.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $890.76 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $484.33 | 2023-2025 | |
| Lilly USA, LLC | $414.28 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $144.35 | 2025 | Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $104.31 | 2023-2025 | |
| Boston Scientific Corporation | $76.39 | 2025 | General - Pain Management |
| Merck Sharp & Dohme LLC | $65.10 | 2023-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Dynavax Technologies Corporation | $58.69 | 2023-2024 | Heplisav-B |
| Otsuka America Pharmaceutical, INC. | $53.71 | 2025 | Rexulti |
| Gilead Sciences, INC. | $52.77 | 2023-2025 | |
| Exact Sciences Corporation | $48.44 | 2025 | Cologuard Collection Kit |
| Viiv Healthcare Company | $45.44 | 2024 | Apretude |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.75 | 2025 | Jardiance |
| Shield Therapeutics INC | $38.89 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $33.96 | 2023 | Quviviq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $33.16 | 2023-2025 | Nexplanon |
| Axsome Therapeutics, INC. | $32.54 | 2024-2025 | Auvelity |
| Inspire Medical Systems, INC. | $32.33 | 2023-2025 | Inspire |
| Pfizer INC. | $31.36 | 2023 | |
| Smith+Nephew, INC. | $28.48 | 2025 | Grafix Pl, Grafix |
| Lucid Diagnostics INC. | $27.59 | 2023 | |
| Mayne Pharma Commercial LLC | $25.80 | 2023 | |
| Corcept Therapeutics | $24.47 | 2024 | Korlym |
| Ultragenyx Pharmaceutical INC. | $21.61 | 2023 | Crysvita |
| Dexcom, INC. | $21.35 | 2022 | |
| Edwards Lifesciences Corporation | $20.64 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.67 | 2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $17.45 | 2025 | Spravato |
| Cranial Technologies, INC | $17.15 | 2023 | Doc Band |
| Glaxosmithkline, LLC. | $15.50 | 2025 | Arexvy, Shingrix |
| Tactile Systems Technology INC | $14.39 | 2024 | Flexitouch Plus, Entre Plus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.47 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $13.43 | 2025 | Voquezna |
| Medtronic, INC. | $13.10 | 2023 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Pettit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.